Infinity Pharmaceuticals, Inc. — Cyborg Score 1/10
Challenged
Immuno-Oncology / Biopharmaceuticals
Strategic Profile
Prior to bankruptcy, Infinity pursued a collaboration-driven strategy with major pharmaceutical partners including Roche/Genentech, Bristol Myers Squibb, and other biotech companies to advance eganelisib combinations across multiple cancer indications. The company's competitive advantage centered on its novel mechanism targeting myeloid cell reprogramming within the tumor microenvironment, positioning it as a potential best-in-class immuno-oncology therapy when combined with checkpoint inhibitors.
Cyborg Score Rationale
The company is in Chapter 11 liquidation as of March 2024, rendering operational and financial metrics obsolete. While eganelisib demonstrated clinical potential with multiple ongoing trials and major pharma partnerships, the bankruptcy filing and liquidation plan mean the company no longer operates as a going concern. Shareholders and stakeholders face significant losses.
Top Insights
Lead asset eganelisib (IPI-549) showed clinical promise in PI3K-gamma inhibition for immuno-oncology, particularly in combination with Tecentriq and Abraxane in TNBC and RCC
Multiple strategic partnerships with Roche, Bristol Myers Squibb, and Arcus Biosciences expanded pipeline reach before bankruptcy
September 2023 Chapter 11 bankruptcy filing and March 2024 liquidation approval ended operations as ongoing concern
Clinical trials evaluating eganelisib were discontinued or transferred as part of bankruptcy proceedings
Named Competitors
Opdivo — PD-1 checkpoint inhibitor for immuno-oncology
Keytruda — PD-1 checkpoint inhibitor for multiple cancer types
Tecentriq — PD-L1 checkpoint inhibitor in combination therapies
Recent Developments
(September 2023) Filed for Chapter 11 bankruptcy reorganization
(March 2024) Chapter 11 liquidation plan approved
(2019) Initiated MARIO-3 and multiple clinical trials for eganelisib in combination therapies
Open the full interactive Infinity Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.